FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation

Programmed death‐ligand 1 (PD‐L1) is a major target to cancer immunotherapy, and anti‐PD‐L1 and anti‐PD‐1 antibody‐mediated immunotherapy are being increasingly used. However, immune checkpoint inhibitors (ICIs) are ineffective in treating large tumors and cause various immune‐related adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhi, Hamadi, Lee, Jeon‐Soo, Choi, Young Eun, Li, Yan, Kim, Myoung Hee, Choi, Yongdoo, Goh, Sung‐Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561767/
https://www.ncbi.nlm.nih.gov/pubmed/35975458
http://dx.doi.org/10.1002/advs.202202702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561767/
https://www.ncbi.nlm.nih.gov/pubmed/35975458
http://dx.doi.org/10.1002/advs.202202702

Ejemplares similares